AstraZeneca said to have explored Bristol Myers merger

AstraZeneca Plc is rumored to have investigated the possibility of acquiring Bristol Myers Squibb Co., a move that could forge one of the world's largest pharmaceutical companies, disclosed individuals familiar with the situation. The two corporations reportedly initiated preliminary talks about a potential consolidation, though the matter remains confidential, according to the sources who declined to be identified due to its private nature.

The veracity of these discussions and their potential conclusion remains uncertain, cautioned the sources. A representative for AstraZeneca did not provide any comment, while Bristol Myers Squibb has not responded to inquiries regarding the talks, which were originally reported by the Financial Times. Bristol Myers Squibb, boasting a $133 billion market capitalization, could significantly enhance AstraZeneca's presence in the United States market.

AstraZeneca's valuation stands at approximately £196 billion ($264 billion). Bristol Myers Squibb is bracing for the expiration of patent protection on several key products, including the blood thinner Eliquis and the cancer drug Opdivo, which together account for about half of the company's sales. Last week, Bristol reported quarterly sales of $13 billion, setting a record.

Growth was primarily attributed to newer products such as the blood cancer treatment Breyanzi, the skin cancer medication Opdualag, and the heart drug Camzyos.